Welcome to our dedicated page for Frequency Therapeutics news (Ticker: FREQ), a resource for investors and traders seeking the latest updates and insights on Frequency Therapeutics stock.
Frequency Therapeutics, Inc. (FREQ) is a biopharmaceutical company that focuses on developing therapies to restore lost sensory function. Founded in 2014 and headquartered in Lexington, Massachusetts, the company aims to harness the body's natural ability to repair and regenerate. Frequency Therapeutics' pioneering work revolves around the advancement of progenitor cell activation (PCA) technology, a method designed to stimulate cells in the body to replace damaged or degenerated tissues.
The company's flagship product candidate, FX-322, is under clinical development for the treatment of sensorineural hearing loss, the most common type of hearing impairment. FX-322 has shown promising results in early-phase clinical trials, indicating a potential breakthrough in a field where limited treatment options exist. Frequency Therapeutics is currently engaged in multiple clinical studies to validate the efficacy and safety of FX-322, aiming to address a significant unmet medical need.
Aside from its core focus on hearing loss, Frequency Therapeutics is expanding its research into other areas of regenerative medicine. The company collaborates with renowned research institutions and partners with industry leaders to accelerate the development and commercialization of innovative therapies. Financially, Frequency Therapeutics has garnered substantial funding through public offerings and strategic partnerships, ensuring robust resources for its ambitious research and development endeavors.
With a steadfast commitment to improving patient lives through cutting-edge science, Frequency Therapeutics continues to advance its clinical programs and explore new therapeutic applications of PCA technology. Investors and stakeholders are closely following the company's progress, anticipating significant advancements in regenerative medicine.
Frequency Therapeutics has completed enrollment for its FX-322-208 Phase 2b study, focusing on patients with acquired sensorineural hearing loss. The study, involving 142 participants, aims to assess improvements in speech perception with results expected in Q1 2023. The company has aligned with the FDA on the primary endpoint and reports a favorable safety profile for FX-322. This study signifies a step toward potential Phase 3 trials if outcomes are positive.
Frequency Therapeutics (Nasdaq: FREQ) announced participation in upcoming investor and medical conferences. CEO David Lucchino will present at the HC Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 11 a.m. EST. He will also present at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 12:50 p.m. EST. Kevin Franck, Ph.D., will discuss FX-322 trial results at the American Academy of Otolaryngology meeting on September 13, 2022, at 5 p.m. EST. Access to live webcasts will be available on Frequency's website.
Frequency Therapeutics (FREQ) announced significant updates in its clinical pipeline and Q2 2022 financial results. The Phase 2b study for FX-322-208 aimed at sensorineural hearing loss is progressing, with readout expected in Q1 2023. The company plans to start enrollment for FX-345 in Q4 2022. The remyelination program for multiple sclerosis is advancing towards IND-enabling studies, with clinical trials anticipated in 2023. Financially, FREQ holds $111 million in cash, sufficient to fund operations into 2024, despite reporting no revenue for Q2 2022 and a net loss of $21.3 million.
Frequency Therapeutics, Inc. (NASDAQ: FREQ) announced that its Chief Scientific Officer, Dr. Christopher Loose, will present at the H.C. Wainwright Global Investment Conference on May 24, starting at 7:00 a.m. ET. The presentation can be accessed through the investors section of Frequency's website. Frequency Therapeutics focuses on regenerative medicine, targeting hearing loss and multiple sclerosis (MS) through innovative therapeutics that activate innate regenerative potential. Its lead candidate, FX-322, aims to restore hearing function and shows promising results in clinical trials.
Frequency Therapeutics (FREQ) reported progress in its clinical pipeline, particularly for the FX-322-208 Phase 2b study targeting acquired sensorineural hearing loss. With cash and cash equivalents at $124.8 million as of March 31, 2022, the company has sufficient runway to fund operations into 2024. While no revenue was recorded for Q1 2022, a net loss of $23.4 million was reported, up from $20.4 million in Q1 2021. The company remains focused on achieving significant clinical milestones, including submission of an IND for FX-345 and continued enrollment in ongoing studies.
Frequency Therapeutics (NASDAQ: FREQ) announced that Chief Scientific Officer Dr. Christopher Loose and Vice President Dr. Sanjay Magavi will present at the B. Riley Securities Neuro & Ophthalmology Conference on April 28, 2022, at 3:30 PM ET. The event will showcase the company's advancements in regenerative medicine, particularly in hearing loss treatment. A live webcast of the presentation will be available on Frequency’s website, with a replay post-event. Frequency is pioneering therapeutics aimed at restoring function through innate regenerative potential activation.
Frequency Therapeutics (Nasdaq: FREQ) reported steady enrollment in the FX-322-208 Phase 2b study aimed at addressing sudden and noise-induced sensorineural hearing loss (SNHL), with topline results expected by Q4 2022 or Q1 2023. The company also advanced its FX-345 program and plans to submit an IND application in H2 2022. Financially, Frequency noted a revenue decline to $14.1 million for 2021, down from $37.0 million in 2020, alongside a net loss of $84.7 million due to increased R&D expenses. Cash reserves of $142.4 million are projected to fund operations through 2023.
Frequency Therapeutics (FREQ) announced CEO David L. Lucchino's participation in two investor conferences. The Cowen 42nd Annual Health Care Conference will feature a corporate panel discussion on March 7, 2022, from 2:10 p.m. to 3:10 p.m. EST. The Oppenheimer 32nd Annual Healthcare Conference will include a company overview presentation on March 16, 2022, from 3:20 p.m. to 3:50 p.m. EST. Investors can access live webcasts on the company's website, with replays available post-event. Frequency focuses on regenerative medicine, particularly for hearing loss and multiple sclerosis.
Frequency Therapeutics (Nasdaq: FREQ) announced that CEO David L. Lucchino will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, at 10:30 a.m. ET. This presentation will cover milestones for its Phase 2b study of FX-322, plans for its second hearing restoration asset FX-345, and a lead candidate for a new multiple sclerosis program. The event will include a live Q&A session, accessible via Frequency's investor website, with a replay available afterwards.
Frequency Therapeutics (NASDAQ: FREQ) announced results from its FX-322-113 study, a Phase 1b trial targeting severe sensorineural hearing loss (SNHL). The study showed significant improvements in hearing signals, with four subjects demonstrating over 3.1 dB enhancements in a sentence-in-noise test. FX-322 aims to regenerate auditory hair cells to restore hearing function. The positive safety profile, with no serious adverse events, supports the potential of FX-322 as a regenerative treatment. Frequency is also enrolling a Phase 2b trial for noise-induced SNHL.
FAQ
What is the market cap of Frequency Therapeutics (FREQ)?
What does Frequency Therapeutics, Inc. specialize in?
What is FX-322?
Where is Frequency Therapeutics headquartered?
When was Frequency Therapeutics founded?
What is progenitor cell activation (PCA) technology?
Has FX-322 shown positive results in clinical trials?
Is Frequency Therapeutics involved in other areas besides hearing loss?
How is Frequency Therapeutics funded?
Does Frequency Therapeutics collaborate with other institutions?
What is the significance of Frequency Therapeutics' work?
